Mesoblast (ASX: MSB; Nasdaq: MESO) delivered US$115M in Ryoncil net revenue in its first full year post-launch (FY2026), completing its transition from a clinical-stage biotech into a commercial company. In its FY2026 Financial Results and Operational Update presentation, released August 2026, management detailed how Mesoblast lifted total revenue to US$120.25M, up from US$17.2M in FY2025.
Ryoncil is the first and only mesenchymal stromal cell (MSC) therapy approved by the US Food and Drug Administration (FDA), and franchise profits are being reinvested into a Phase 3 pipeline targeting multiple blockbuster indications.
Key headline metrics from the presentation included gross profit of US$104M, gross profit on total sales excluding amortisation of US$110M, a cash balance of US$103M at 30 June 2026, and a loss after tax narrowed to US$57.5M from US$102.1M in FY2025.
FY2026 financial results: revenue leaps to US$120M
The presentation outlined a full-year turnaround driven by Ryoncil’s US commercialisation. Product sales net reached US$115.2M, up from US$11.3M the prior year, supplemented by royalty revenue of US$5.1M.
Management noted an additional US$39.7M invested in research and development during the period, after adjusting for a US$23M prior-period inventory benefit. This comprised US$17.3M on product development across the remestemcel-L and rexlemestrocel-L platforms, and US$21.2M on Phase 3 clinical trials and regulatory filing activities.
Selling, general and administrative (SG&A) expenses rose approximately US$18M to US$57.3M, reflecting the cost of building the commercial team and launching Ryoncil.
Net operating cash usage improved to US$43.8M for FY2026, down from US$50.0M in FY2025, with just US$13.4M consumed in the second half. A new US$125M credit line replaced existing higher-cost debt.
| Metric (US$’000) | FY2026 | FY2025 | Commentary |
|---|---|---|---|
| Total revenues | 120,250 | 17,198 | Driven by Ryoncil US launch |
| Cost of revenues | (16,667) | (5,130) | Scaled with product sales |
| Research & development | (97,509) | (34,807) | Phase 3 pipeline investment |
| Selling, general & admin | (57,346) | (39,309) | Commercial team and launch costs |
| Loss after income tax | (57,500) | (102,142) | Narrowed on revenue growth |
When big ASX news breaks, our subscribers know first
What is an allogeneic MSC therapy, and why does Mesoblast’s ‘moat’ matter?
Ryoncil being the first and only FDA-approved MSC is significant because it provides a first-mover position in a therapeutic category with no direct approved competitor. Management framed this as the company’s “MOAT”.
Central to that position is a global intellectual property (IP) portfolio of more than 1,100 patents and patent applications, providing protection through beyond 2044. The company also cited its ability to leverage FDA guidance on approved products to pursue label extensions, alongside complex manufacturing know-how and scale-up capacity.
For investors, this moat underpins a scalable commercial model and defends the potential value of future blockbuster indications.
Ryoncil launch milestones: US$125M in cumulative revenue and 98% coverage
The presentation detailed strong early commercial execution in paediatric steroid-refractory acute graft versus host disease (SR-aGvHD), a life-threatening complication that can occur after a stem cell transplant.
Launch metrics highlighted included:
-
84% survival outcomes in initial real-world experience, all Grade III/IV disease, after completing 28 days of treatment
-
Net revenue exceeding US$125M since launch
-
More than 50 centers onboarded
-
30+ formulary approvals
-
98% of US lives covered
-
Medicaid J-Code received October 2025
Management outlined four strategic commercial priorities: identifying and prioritising appropriate patients, reinforcing superior first-line outcomes, enhancing access and reimbursement pull-through, and empowering caregivers. Q4 net revenue of US$36M was presented as evidence of continued momentum.
The adult SR-aGvHD opportunity: a market ~3x larger than paediatric
Management positioned the adult SR-aGvHD indication as the key near-term expansion lever. The presentation noted more than 2,000 adults annually in the US develop SR-aGvHD, of which roughly 50% have Grade III/IV disease.
A registration trial for label extension is underway, enrolling 180 adults randomised 1:1 to ruxolitinib versus ruxolitinib plus Ryoncil, across approximately 40 US centers, with site activation initiated.
The trial is expected to run around 18 months, with an interim analysis for potential early success expected in Q4 CY2027, when the first 102 patients (57% enrolled) reach the Day 28 primary endpoint.
On survival, the presentation cited 76% at Day 100 with Ryoncil after ruxolitinib failure, compared with approximately 25% with other agents. A separate third-line potential market of more than 600 patients annually was also identified. The adult market is described as around three times the size of the paediatric opportunity, with total aGvHD addressable market of approximately US$1B.
Blockbuster Phase 3 pipeline: chronic low back pain and heart failure
Management detailed two rexlemestrocel-L (STRO3+) programs as longer-term value drivers.
Chronic low back pain (CLBP) — >US$10B TAM
The presentation confirmed 350 patients treated in the Phase 3 trial, increased from 300 on strong investigator demand, with patient treatment completed August 2026. Around 35M US patients suffer from CLBP, of which approximately 60% is due to degenerative disc disease.
Phase 3 data showed significant pain reduction through 36 months for Rexlemestrocel-L plus hyaluronic acid (HA), and management cited that 85% of pain specialists were more likely to recommend the therapy based on 12-month outcomes. Trial readout is expected in H2 CY2027, followed by a Biologics License Application (BLA) filing and potential approval in CY2028.
The back pain Phase 3 data readout in H2 CY2027 will mark the first major efficacy test of rexlemestrocel-L at commercial scale, with 350 patients treated across a trial expanded beyond its original 300-patient target on strong investigator demand.
End-stage heart failure with LVAD — >US$10B TAM
REVASCOR reduced major mucosal bleeding events and reduced ischaemic-patient mortality from 30% to 9% (p=0.03). Major GI bleeding is an FDA-acknowledged indication, with REVASCOR having received Orphan Drug designation.
Management outlined a strategy to file a BLA for LVAD patients, which is intended to facilitate subsequent label extension into pre-LVAD NYHA Class II/III HFrEF patients.
| Product | Indication | Stage | Key Catalyst / Timeline | TAM |
|---|---|---|---|---|
| RYONCIL (remestemcel-L) | Paediatric SR-aGvHD | Approved | Grow US penetration | ~US$1B (combined Paediatric and Adult SR-aGvHD) |
| RYONCIL (remestemcel-L) | Adult SR-aGvHD | Phase 3 | Interim analysis Q4 CY2027 | |
| RYONCIL (remestemcel-L) | Duchenne’s | Phase 3 (IND cleared) | Phase 3 program | >US$1B |
| Rexlemestrocel-L (STRO3+) | CLBP | Phase 3 | Readout H2 CY2027; approval CY2028 | >US$10B |
| REVASCOR (rexlemestrocel-L) | End-stage HFrEF / LVAD | Phase 3 | BLA filing for LVAD patients | >US$10B |
The presentation also noted out-licensing arrangements: JCR Pharmaceuticals for Japan, Grünenthal holding an exclusive license to develop and commercialise rexlemestrocel-L for chronic low back pain in Europe and Latin America/Caribbean, and Tasly Pharmaceuticals holding exclusive rights for rexlemestrocel-L for the treatment or prevention of chronic heart failure in China.
Management on the transition to a commercial company
Positioning summary (paraphrased from the presentation)
Management positioned FY2026 as the year Mesoblast transitioned to a commercial company, marked by the successful first US launch of Ryoncil and the delivery of major milestones. The company pointed to its strong financial position, with Ryoncil franchise profitability being reinvested into the Phase 3 pipeline, supported by a US$103M cash balance and a new US$125M credit line.
What comes next for Mesoblast
The presentation closed with a forward-looking roadmap of catalysts:
-
Grow paediatric SR-aGvHD penetration and revenue base
-
Advance the adult SR-aGvHD registration trial, with interim analysis expected Q4 CY2027
-
Progress the paediatric Duchenne’s Phase 3 program, following FDA clearance of the IND
-
Complete the CLBP Phase 3 trial mid-CY2027, followed by a BLA filing
-
Complete the REVASCOR BLA filing for end-stage HFrEF patients with LVAD
Management reiterated that Ryoncil franchise profits are being reinvested into the pipeline, supported by a US$103M cash balance and the new US$125M credit line providing operational runway.
Don’t Miss the Next Healthcare Breakthrough on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next major ASX healthcare announcement the moment it drops.